-

Shareholder Alert: Robbins LLP Announces Fifth Third Bancorp (FITB) Sued for Misleading Shareholders

SAN DIEGO & CINCINNATI--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Fifth Third Bancorp (NASDAQ: FITB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 26, 2016 and March 6, 2020. Fifth Third operates as a diversified financial services company in the United States.

If you suffered a loss as a result of Fifth Third's misconduct, click here.

Fifth Third Bancorp (FITB) Accused of Misleading Shareholders

According to the complaint, throughout the relevant period, Fifth Third continuously touted its "cross-sell" strategy to increase products and services and its robust compliance risk management systems. Then, on March 2, 2020, Fifth Third disclosed in its annual report for 2019 that the U.S. Consumer Financial Protection Bureau ("CFPB") "notified Fifth Third that it intends to file an enforcement action in relation to alleged unauthorized account openings." Finally, on March 9, 2020, the CFPB announced that it filed a lawsuit against Fifth Third in federal court alleging that for several years and until at least 2016, "Fifth Third without consumer's knowledge or consent: opened deposit and credit-card accounts in consumers' names; transferred funds from consumers' existing accounts to new, improperly opened accounts; enrolled consumers in unauthorized online-banking services; and activated unauthorized lines of credit on consumers' accounts." The CFPB further alleged that Fifth Third knew of the wrongdoing since 2008 but failed to take sufficient steps to stop the conduct and remediate harmed consumers. On this news, Fifth Third's stock price fell 13% over the next three trading days to close at $15.90 per share.

Fifth Third Bancorp (FITB) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:FITB

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom